Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Machine Learning-based Exceptional Response Prediction of Nivolumab Monotherapy with Circulating MicroRNAs in Non-Small Cell Lung Cancer

ABSTRACT: Machine Learning-based Exceptional Response Prediction of Nivolumab Monotherapy with Circulating MicroRNAs in Non-Small Cell Lung Cancer

PROVIDER: PRJNA849256 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR19658700.fastq.gz	Fastqsanger.gz
	SRR19658702.fastq.gz	Fastqsanger.gz
	SRR19658705.fastq.gz	Fastqsanger.gz
	SRR19658805.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 115

Similar Datasets

Machine Learning-based Exceptional Response Prediction of Nivolumab Monotherapy with Circulating MicroRNAs in Non-Small Cell Lung Cancer

Project description:Detecting cancer patients with exceptional response to immune check-point inhibition therapy is necessary to improve the treatment. This study demonstrated machine learning models that utilize both microRNA expression and clinical information achieved much higher sensitivity and accuracy in identifying Exceptional-responder to nivolumab monotherapy when comparing to conventional method only using companion PD-L1 testing.

2025-06-14 | GSE206127 | GEO

Prediction of Breast Cancer Estrogen Receptor Status using Machine Learning

Project description:Gene expression profiles were generated from 199 primary breast cancer patients. Samples 1-176 were used in another study, GEO Series GSE22820, and form the training data set in this study. Sample numbers 200-222 form a validation set. This data is used to model a machine learning classifier for Estrogen Receptor Status. RNA was isolated from 199 primary breast cancer patients. A machine learning classifier was built to predict ER status using only three gene features.

2013-01-01 | E-GEOD-29210 | biostudies-arrayexpress

Prediction of Breast Cancer Estrogen Receptor Status using Machine Learning

2013-01-01 | GSE29210 | GEO

Machine learning-based prediction of the activity and specificity of Cas9 variants in gene editing

Project description:Machine learning-based prediction of the activity and specificity of Cas9 variants in gene editing

2024-08-22 | GSE231840 | GEO

Machine learning-optimized targeted detection of alternative splicing

Project description:RNA-sequencing (RNA-seq) is widely used for analysis of alternative splicing, but in practice, has inherent biases which hinder its ability to detect and quantify splicing events. To address this, we present a targeted RNA-seq method that specifically enriches for splicing-informative junction-spanning reads. Local Splicing Variation sequencing (LSV-seq) utilizes multiplexed reverse transcription from highly scalable pools of primers anchored near splice junctions of interest. Primers are designed using Optimal Prime, a novel dedicated machine learning algorithm trained on the performance of thousands of primer sequences. LSV-seq achieves high on-target capture rates and concordance with RNA-seq, while requiring several-fold lower sequencing depth. We use LSV-seq to target events with low coverage in GTEx RNA-seq data and discover hundreds of previously hidden tissue-specific splicing events. Our results demonstrate the ability of LSV-seq to capture alternative splicing with exceptional sensitivity and highlight its potential to improve the detection of other RNA features of interest.

2024-12-27 | GSE246294 | GEO

RNA sequensing data of a phase 2 clinical trial of pancreatic ductal adenocarcinoma treated with entinostat in combination with nivolumab

Project description:We conducted a single-center, open-label, Simon two-stage, phase II study of entinostat in combination with the PD1 inhibitor nivolumab in patients with advanced pancreatic ductal adenocarcinoma. Patients received oral entinostat 5 mg once a week. After a 14-day lead-in with entinostat monotherapy, patients concurrently receive entinostat 5 mg orally once a week plus nivolumab 240 mg intravenously until the time of progression or unacceptable toxicities.

2024-07-29 | GSE248014 | GEO

NCI Exceptional Responders Initiative

Project description:NCI Exceptional Responders Initiative

| PRJNA325186 | ENA

A machine learning-enhanced methodology for accurate prediction of enzyme-substrate selection

Project description:Dataset supporting the identification of machine learning-lead validation of SET8 substrates using targeted mass spectrometry (PRM-MS).

2025-02-22 | PXD050037 | JPOST Repository

Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small-cell lung cancer

Project description:We report RNA-sequencing data of 286 platelet RNA samples isolated from non-small cell lung cancer patients (NSCLC) that were at baseline for nivolumab immunotherapy. This dataset was employed to test the hypothesis that platelet RNA at baseline of nivolumab treatment predicts immune responses.

2023-07-10 | GSE216297 | GEO

Establishment of interpretable cytotoxicity prediction models using machine learning analysis of transcriptome features

Project description:Cytotoxicity, usually represented by cell viability, is a crucial parameter for evaluating drug safety in vitro. Accurate prediction of cell viability/cytotoxicity could accelerate drug development in the early stage. In this study, by using machine learning algorithms on cellular transcriptome and cell viability data, highly accurate prediction models of 50% and 80% cell viability were developed with AUROCs of 0.90 and 0.84, respectively, which also showed good performance on diverse cell lines. With respect to the characterization of Feature Genes employed, the models can be interpreted, and the mechanisms of bioactive compounds with narrow therapeutic indices can also be analyzed. In summary, the models established in this study have the capacity to predict cytotoxicity highly accurately across cell lines and can be used for high safety substances screening efficiently. Moreover, the Cytotoxicity Signature genes from interpretability analysis is valuable for studying the mechanisms of action, especially for substances with narrow therapeutic indices.

2025-05-28 | GSE252529 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data